Clinical diagnosis and treatment of immune checkpoint inhibitor‐associated pneumonitis

The increasing use of immune checkpoint inhibitors in tumors has brought new hope of survival to patients with advanced tumors. However, the immune system activated by immune checkpoint inhibitors, mainly activated T‐cells, can attack normal tissues and organs in the body and lead to a variety of ad...

Full description

Bibliographic Details
Main Authors:	Hanping Wang, Xiaoxiao Guo, Jiaxin Zhou, Yue Li, Lian Duan, Xiaoyan Si, Li Zhang, Xiaowei Liu, Mengzhao Wang, Juhong Shi
Format:	Article
Language:	English
Published:	Wiley 2020-01-01
Series:	Thoracic Cancer
Subjects:	Checkpoint inhibitor pneumonitis immune checkpoint inhibitor immune checkpoint inhibitor‐related adverse effects immunotherapy‐related toxicity
Online Access:	https://doi.org/10.1111/1759-7714.13240

id	doaj-26b6dfa110fa45b580f11fb126442aeb
record_format	Article
spelling	doaj-26b6dfa110fa45b580f11fb126442aeb2020-11-25T01:28:22ZengWileyThoracic Cancer1759-77061759-77142020-01-0111119119710.1111/1759-7714.13240Clinical diagnosis and treatment of immune checkpoint inhibitor‐associated pneumonitisHanping Wang0Xiaoxiao Guo1Jiaxin Zhou2Yue Li3Lian Duan4Xiaoyan Si5Li Zhang6Xiaowei Liu7Mengzhao Wang8Juhong Shi9Li Zhang10Department of Respiratory Medicine Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences Beijing ChinaDepartment of Cardiology Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences Beijing ChinaDepartment of Rheumatism and Immunology Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences Beijing ChinaDepartment of Digestive Medicine Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences Beijing ChinaDepartment of Endocrinology Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences Beijing ChinaDepartment of Respiratory Medicine Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences Beijing ChinaDepartment of Clinical Laboratory Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences Beijing ChinaDepartment of Ophthalmology Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences Beijing ChinaDepartment of Respiratory Medicine Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences Beijing ChinaDepartment of Respiratory Medicine Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences Beijing ChinaDepartment of Respiratory Medicine Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences Beijing ChinaThe increasing use of immune checkpoint inhibitors in tumors has brought new hope of survival to patients with advanced tumors. However, the immune system activated by immune checkpoint inhibitors, mainly activated T‐cells, can attack normal tissues and organs in the body and lead to a variety of adverse effects. In the lung, these attacks can induce checkpoint inhibitor pneumonitis (CIP). CIP is different from known pulmonary interstitial pneumonitis, and has the potential to be fatal if not treated correctly. In this review, we summarize the characteristics of CIP and provide advice on how to manage this disease.https://doi.org/10.1111/1759-7714.13240Checkpoint inhibitor pneumonitisimmune checkpoint inhibitorimmune checkpoint inhibitor‐related adverse effectsimmunotherapy‐related toxicity
collection	DOAJ
language	English
format	Article
sources	DOAJ
author	Hanping Wang Xiaoxiao Guo Jiaxin Zhou Yue Li Lian Duan Xiaoyan Si Li Zhang Xiaowei Liu Mengzhao Wang Juhong Shi Li Zhang
spellingShingle	Hanping Wang Xiaoxiao Guo Jiaxin Zhou Yue Li Lian Duan Xiaoyan Si Li Zhang Xiaowei Liu Mengzhao Wang Juhong Shi Li Zhang Clinical diagnosis and treatment of immune checkpoint inhibitor‐associated pneumonitis Thoracic Cancer Checkpoint inhibitor pneumonitis immune checkpoint inhibitor immune checkpoint inhibitor‐related adverse effects immunotherapy‐related toxicity
author_facet	Hanping Wang Xiaoxiao Guo Jiaxin Zhou Yue Li Lian Duan Xiaoyan Si Li Zhang Xiaowei Liu Mengzhao Wang Juhong Shi Li Zhang
author_sort	Hanping Wang
title	Clinical diagnosis and treatment of immune checkpoint inhibitor‐associated pneumonitis
title_short	Clinical diagnosis and treatment of immune checkpoint inhibitor‐associated pneumonitis
title_full	Clinical diagnosis and treatment of immune checkpoint inhibitor‐associated pneumonitis
title_fullStr	Clinical diagnosis and treatment of immune checkpoint inhibitor‐associated pneumonitis
title_full_unstemmed	Clinical diagnosis and treatment of immune checkpoint inhibitor‐associated pneumonitis
title_sort	clinical diagnosis and treatment of immune checkpoint inhibitor‐associated pneumonitis
publisher	Wiley
series	Thoracic Cancer
issn	1759-7706 1759-7714
publishDate	2020-01-01
description	The increasing use of immune checkpoint inhibitors in tumors has brought new hope of survival to patients with advanced tumors. However, the immune system activated by immune checkpoint inhibitors, mainly activated T‐cells, can attack normal tissues and organs in the body and lead to a variety of adverse effects. In the lung, these attacks can induce checkpoint inhibitor pneumonitis (CIP). CIP is different from known pulmonary interstitial pneumonitis, and has the potential to be fatal if not treated correctly. In this review, we summarize the characteristics of CIP and provide advice on how to manage this disease.
topic	Checkpoint inhibitor pneumonitis immune checkpoint inhibitor immune checkpoint inhibitor‐related adverse effects immunotherapy‐related toxicity
url	https://doi.org/10.1111/1759-7714.13240
work_keys_str_mv	AT hanpingwang clinicaldiagnosisandtreatmentofimmunecheckpointinhibitorassociatedpneumonitis AT xiaoxiaoguo clinicaldiagnosisandtreatmentofimmunecheckpointinhibitorassociatedpneumonitis AT jiaxinzhou clinicaldiagnosisandtreatmentofimmunecheckpointinhibitorassociatedpneumonitis AT yueli clinicaldiagnosisandtreatmentofimmunecheckpointinhibitorassociatedpneumonitis AT lianduan clinicaldiagnosisandtreatmentofimmunecheckpointinhibitorassociatedpneumonitis AT xiaoyansi clinicaldiagnosisandtreatmentofimmunecheckpointinhibitorassociatedpneumonitis AT lizhang clinicaldiagnosisandtreatmentofimmunecheckpointinhibitorassociatedpneumonitis AT xiaoweiliu clinicaldiagnosisandtreatmentofimmunecheckpointinhibitorassociatedpneumonitis AT mengzhaowang clinicaldiagnosisandtreatmentofimmunecheckpointinhibitorassociatedpneumonitis AT juhongshi clinicaldiagnosisandtreatmentofimmunecheckpointinhibitorassociatedpneumonitis AT lizhang clinicaldiagnosisandtreatmentofimmunecheckpointinhibitorassociatedpneumonitis
_version_	1725102224979263488

Clinical diagnosis and treatment of immune checkpoint inhibitor‐associated pneumonitis

Similar Items